Peripheral Vertigo (BPPV-Refractory / Vestibular Neuritis Recovery)
Investigational adjunct for peripheral vertigo persisting after Epley maneuvers or during prolonged vestibular neuritis recovery; no study specific to these conditions was identified.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for refractory peripheral vertigo / vestibular neuritis recovery. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No controlled trial or other study of leech therapy in BPPV or vestibular neuritis was identified. Evidence-based first-line management of BPPV is canalith repositioning maneuvers (Epley, Semont) which resolve 80-90% of cases in 1-3 sessions; for vestibular neuritis the standard is short-course steroids in the acute phase plus vestibular rehabilitation. Leeches should only be considered after these have been adequately tried.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Transient worsening of dizziness during and shortly after sessions
- Who should not consider this
- Patients whose BPPV has not been adequately treated with at least 2-3 Epley or Semont maneuvers by a vestibular specialist
- Patients with central vertigo (cerebellar stroke, demyelinating disease) — leeches will not help and may delay diagnosis
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- Patients who are pregnant (leech therapy is not done during pregnancy) or breastfeeding (discuss it with your doctor)
- What to ask your clinician
- Has my vertigo been evaluated by a vestibular specialist to confirm it is peripheral and not central?
- Have I had a proper trial of Epley or Semont maneuvers (the standard BPPV treatment)?
- Could my symptoms be better explained by another vestibular condition that has a specific evidence-based treatment?
- What is the published evidence base for leech therapy in this condition?
- How will improvement be measured objectively, not just by my report?
- Will leeches interfere with vestibular rehabilitation exercises?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden severe headache, double vision, slurred speech, facial droop, or arm or leg weakness (possible stroke)
- Inability to walk or sit up because of dizziness lasting more than a few hours
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for vertigo — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace canalith repositioning maneuvers, which are the proven first-line treatment for BPPV.
- It does not work for central causes of vertigo, which require neurology rather than ENT attention.
- It does not have controlled-trial evidence for any vertigo subtype.
- It does not accelerate vestibular compensation beyond what targeted rehabilitation already provides.
Safety cross-references
Clinical Profile
- Category
- ENT
- ICD-10
- H81.10, H81.11, H81.12, H81.13, H81.20, H81.23
- Safety tier
- Medium
Evidence Summary
Peripheral vertigo encompasses BPPV (usually resolved by canalith repositioning), vestibular neuritis, and labyrinthitis. No clinical study of leech therapy for BPPV or vestibular neuritis was identified — particle repositioning maneuvers (Epley, Semont) remain first-line — and no controlled trial of leech therapy for peripheral vertigo was identified. The only indirect clinical data are uncontrolled Russian series in peripheral cochleovestibular disorders of vascular origin, in which vertigo was one of several symptoms (Flaum & Shakhov 2008, 209 patients, including 115 with chronic sensorineural hearing loss or labyrinthine dysfunction; Morozova & Aksenova 2009, PMID 19738593); these do not address BPPV or vestibular neuritis. Any adjunctive use in prolonged vestibular recovery is investigational. Use is highly experimental; vestibular rehabilitation therapy remains the evidence-based mainstay.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan do not write specifically about peripheral vertigo or benign positional vertigo: closest to the topic is the observation by Grigoriev and Krymskaya (1998) of 40 patients with sensorineural cochleovestibular (hearing and balance) disorders of predominantly peripheral origin[B1].
- The outcomes are described there as follows: circulatory disturbances in this area were linked to hypertensive disease, atherosclerosis and changes in the properties of the blood, and after treatment all patients noted a lightness in the head and the noise indicators decreased; whether the vertigo changed is not clear from the text, nor is it clear whether there was a comparison group[B1].
- Among other observations, Baskova and Isakhanyan cite data from Mokhov and Zaltsman (1998): in patients with ischemic stroke, after hirudotherapy, by their description, headaches, tinnitus and vertigo decreased; this observation is not about a separate treatment of vertigo[B1].
- Michalsen et al. do not write about vertigo as an indication for hirudotherapy[B3].
- This is a general caution from the book, not information about vertigo as a disease: in the chapter on safety, Michalsen writes that patients who have previously had vasovagal attacks or fainting may develop such a reaction at the start of or during hirudotherapy; according to one survey, this happened in his hospital about once in 1000 treatments, and to prevent it he advises drinking enough fluids and carrying out the treatment in a calm environment while lying down[B3].
- Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias, hypotension, acute vascular insufficiency (shock, collapse, fainting) and concurrent prescription of anticoagulants (their list is longer); Flecken and Michalsen, in the chapter on contraindications, regard congenital or acquired hemophilia and taking anticoagulants as an absolute contraindication[B1][B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Central vertigo (must rule out with MRI brain)
- Active middle ear infection
- Unstable balance with high fall risk
Related Conditions
Ménière's Disease (Adjunctive)
Investigational adjunct for Ménière's disease with no clinical study identified; standard management (diet, betahistine, intratympanic therapy) remains primary.
Subjective Tinnitus
Investigational for tinnitus; small non-randomized studies, mostly Russian, report less ear noise, and no study using the Tinnitus Handicap Inventory was identified.
Chronic Rhinosinusitis
Investigational use for chronic rhinosinusitis; no clinical study of leech therapy for this condition was identified, and the rationale is mechanistic.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; no clinical study of leech therapy for this subtype was identified.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.